WIKIPEDIA, TMHLEE
Update (March 28): Today, doctors administered the first donor-derived iPSC transplant that Takahashi developed, Nature News reported. A man in his 60s received the therapy, aimed at treating macular degeneration. Earlier this year, Takahashi's team reported success using a patient's own iPSCs that were reprogrammed into retinal cells.
Researchers in Japan who have been developing a cell therapy for macular degeneration received support from health authorities this week (February 1) to begin a clinical trial using donor-derived induced pluripotent stem cells (IPSCs) converted to retinal cells. This will be the first trial in which the team’s physicians administer donor cells, an approach expected to lower costs and preparation time.
Previously, this same group of scientists, led by the Riken Center for Developmental Biology’s Masayo Takahashi, ...